All In Biotech

Drug Trial Radar · NCT06938880

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

May 20, 2025

Primary completion

May 2027

Study completion Apr 2028

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.

Conditions

  • Advanced Solid Tumor

Interventions

  • ZGGS18 for InjectionBiological

    Intravenous infusion

  • ZG005 for InjectionBiological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicity(DLT)Time frame: up to 21 days
  2. Adverse Event (AE)Time frame: Up to 2 years
  3. Maximum tolerated dose(MTD)Time frame: Up to 1 years
  4. Recommended phase II dose(RP2D)Time frame: Up to 1 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.